InMed Pharmaceuticals Inc. Files 8-K for Material Agreement
Ticker: INM · Form: 8-K · Filed: Jun 28, 2024 · CIK: 1728328
Sentiment: neutral
Topics: material-agreement, 8-k, regulatory-filing
TL;DR
InMed Pharma signed a big deal, filing an 8-K on June 27th.
AI Summary
On June 27, 2024, InMed Pharmaceuticals Inc. entered into a material definitive agreement. The company, incorporated in British Columbia with its principal executive offices in Vancouver, Canada, filed this 8-K report to disclose this event. The filing also includes financial statements and exhibits.
Why It Matters
This filing indicates a significant business development for InMed Pharmaceuticals, potentially impacting its operations, partnerships, or financial standing.
Risk Assessment
Risk Level: medium — Material definitive agreements can introduce new risks or opportunities, requiring further analysis of the agreement's terms and implications.
Key Numbers
- 001-39685 — SEC File Number (Identifies the company's filing with the SEC)
- 98-1428279 — IRS Employer Identification No. (Company's tax identification number)
Key Players & Entities
- InMed Pharmaceuticals Inc. (company) — Registrant
- June 27, 2024 (date) — Date of earliest event reported
- Vancouver, B.C., Canada (location) — Principal Executive Offices
- 815 W. Hastings Street (location) — Street address of principal executive offices
FAQ
What type of material definitive agreement did InMed Pharmaceuticals Inc. enter into?
The filing states that the company entered into a 'Material Definitive Agreement' but does not specify the nature of the agreement in the provided text.
What is the significance of the 'Item Information: Entry into a Material Definitive Agreement' in this filing?
This indicates a significant event for the company, such as a merger, acquisition, significant contract, or other major business transaction that is considered material to investors.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on June 27, 2024.
Where are InMed Pharmaceuticals Inc.'s principal executive offices located?
The principal executive offices are located at Suite 310 - 815 W. Hastings Street, Vancouver, B.C., Canada.
What is the company's Standard Industrial Classification (SIC) code?
The company's SIC code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 776 words · 3 min read · ~3 pages · Grade level 10.5 · Accepted 2024-06-27 20:32:35
Filing Documents
- ea0208584-8k_inmed.htm (8-K) — 32KB
- ea020858401ex5-1_inmed.htm (EX-5.1) — 14KB
- ea020858401ex10-1_inmed.htm (EX-10.1) — 22KB
- ex5-1_001.jpg (GRAPHIC) — 13KB
- 0001213900-24-056807.txt ( ) — 269KB
- inm-20240627.xsd (EX-101.SCH) — 3KB
- inm-20240627_lab.xml (EX-101.LAB) — 33KB
- inm-20240627_pre.xml (EX-101.PRE) — 22KB
- ea0208584-8k_inmed_htm.xml (XML) — 4KB
01 Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement. On June 27, 2024, InMed Pharmaceuticals Inc., (the "Company") entered into an amendment (the "ATM Amendment") to its At-the-Market Offering Agreement, dated April 7, 2022 (the "Original ATM Agreement" and together with the ATM Amendment, the "Amended ATM Agreement"), by and between the Company and H.C. Wainwright & Co., LLC (the "Agent"), as sales agent, pursuant to which the Company may offer and sell shares of the Company's common shares, no par value per share (the "Common Shares"), from time to time, in "at the market" offerings through the Agent. The Original ATM Agreement was previously filed with the Securities and Exchange Commission on April 7, 2022 on the Company's Current Report on Form 8-K. The ATM Amendment amends the Original ATM Agreement to reflect, among other provisions, updates to certain sales settlement provisions and reimbursement terms, and to supplement the representations being made by the Company to the Agent. The Common Shares sold under the Amended ATM Agreement will be offered and sold pursuant to the Company's shelf registration statement on Form S-3, which was initially filed on February 4, 2022 and amended on February 9, 2022 and was declared effective by the Securities and Exchange Commission on February 11, 2022 (Registration No. 333-262532). The foregoing description of the terms of the ATM Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the ATM Amendment, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference. This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy the common shares that may be sold pursuant to the Amended ATM Agreement, nor shall there be any offer, solicitation or sale of the common shares in any state or country in which such offer, solicitation or sale would be unlawful prior to re
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits: Exhibit No. Description 5.1 Opinion of Norton Rose Fulbright Canada LLP 10.1 Amendment No. 1, dated June 27, 2024, to the At the Market Offering Agreement, dated April 7, 2022, by and between InMed Pharmaceuticals Inc., and H.C. Wainwright & Co., LLC 104 Cover Page Interactive Data File (embedded within the Inline XBRL document and included as Exhibit 101) 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INMED PHARMACEUTICALS INC. Date: June 27, 2024 By: /s/ Eric A. Adams Eric A. Adams President & CEO 2